Yeah. New Drugs are 'new', have probably just gone through expensive R&D and Trial periods, so there is a need to recoup investment. Of course, there's the pro

Yeah. New Drugs are 'new', have probably just gone through expensive R&D and Trial periods, so there is a need to recoup investment. Of course, there's the problem of when companies make a 'new' drug that is very similar to an existing drug/generic that already exists. A great example of that in my head is how Cymbalta is not that much different than Effexor.